S D Berkowitz

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
    S D Berkowitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 32:311-9. 1998
  2. ncbi Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [un
    D B Mark
    Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 97:1702-7. 1998
  3. ncbi Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease
    S D Berkowitz
    Division of Hematology, Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Haemostasis 30:27-43. 2000
  4. ncbi Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)
    C M O'Connor
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 88:541-6. 2001
  5. ncbi Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction
    S D Berkowitz
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 88:1230-4. 2001

Collaborators

Detail Information

Publications5

  1. ncbi Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
    S D Berkowitz
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Coll Cardiol 32:311-9. 1998
    ....
  2. ncbi Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [un
    D B Mark
    Clinical Research Institute, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Circulation 97:1702-7. 1998
    ..No increase in major bleeding was seen...
  3. ncbi Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease
    S D Berkowitz
    Division of Hematology, Duke Clinical Research Institute, Duke University, Durham, NC, USA
    Haemostasis 30:27-43. 2000
    ..They are well tolerated and safe, provided concomitant use with other antithrombotics (e.g. heparin) is carefully managed and platelet counts are monitored...
  4. ncbi Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS)
    C M O'Connor
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Am J Cardiol 88:541-6. 2001
    ..The results of this secondary analysis suggest that aspirin 160 mg is more effective than aspirin 80 mg + warfarin 1 mg in preventing ischemic stroke in post-myocardial infarction patients...
  5. ncbi Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction
    S D Berkowitz
    Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 88:1230-4. 2001
    ....